Arthroscopy Devices Market Worth $9.85Bn, Globally, by 2028 at 8.1% CAGR - Exclusive Report by The Insight Partners
May 23, 2022 08:44 ET
|
The Insight Partners
New York, May 23, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Arthroscopy Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product...
Leading Orthopedic Surgeons at UNOVA Hip & Knee Center Set the Record Straight on Joint Replacements for Arthritis Awareness Month
May 18, 2022 09:15 ET
|
UNOVA Hip & Knee Center
LADY LAKE, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- In honor of Arthritis Awareness Month in May, the experts of UNOVA Hip & Knee Center are setting the record straight when it comes to joint...
PETVIVO HOLDINGS, INC. ANNOUNCES DISTRIBUTION OF ITS VETERINARY MEDICAL DEVICE, SPRYNG™, BY VETCOVE, INC.
January 05, 2022 07:30 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative...
Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis
November 17, 2021 06:00 ET
|
Bone-Tech
AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis...
Bone Therapeutics annonce les résultats principaux de l'étude de Phase III évaluant son viscosupplément amélioré, le JTA-004, dans l'arthrose du genou
August 30, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Aucune différence statistiquement significative n’a été observée dans la réduction de la douleur du genou entre JTA-004, le placebo et le comparateur actif 3 mois après le...
Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
August 30, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
July 19, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Bone Therapeutics provides update on the progress of clinical studies
July 19, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...
Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21, 2021 09:15 ET
|
Biosplice Therapeutics, Inc.
SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsight
May 25, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 25, 2021 (GLOBE NEWSWIRE) -- New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsightApproximately 80+ key companies are developing...